Alluvi, formerly BI 4744, presents a notable breakthrough in weight control therapy. This dual agonist targeting both GLP-1 and GIP receptors demonstrates impressive efficacy in clinical trials, possibly outperforming https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/